Votrient News and Research

RSS
CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

CytRx receives FDA approval to continue dosing aldoxorubicin for patients with soft tissue sarcomas

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Merck initiates clinical trial to evaluate MK-3475 and pazopanib in advanced renal cell carcinoma

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

Pazopanib drug shows improved quality of life and safety in metastatic kidney cancer patients

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

CytRx reaches agreement with FDA for aldoxorubicin Phase 3 trial for treatment of soft tissue sarcomas

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

FDA ODAC votes in favour of GSK's Votrient

FDA ODAC votes in favour of GSK's Votrient

Three new targeted drugs can lead to fatal cancer complications

Three new targeted drugs can lead to fatal cancer complications

Research on rare cancers

Research on rare cancers

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

GSK awards NCCN $4 million grant for study of ofatumumab and pazopanib

Pazopanib drug slows the progression of RCC in patients by 54%

Pazopanib drug slows the progression of RCC in patients by 54%

FDA approves new oral medication for renal cell carcinoma

FDA approves new oral medication for renal cell carcinoma

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018

GlaxoSmithKline's Votrient will take significant market share away from Pfizer's Sutent by 2018